Daiichi Sankyo Company, Limited

4568.T
Drug Manufacturers - General
2026/01/16 Updated
Market Cap: $39.7B (¥6.3T)
Stock Price: $21.46 (¥3,401)
Exchange Rate: 1 USD = ¥158.48

Notice Regarding Status of Treasury Stock Acquisition (Acquisition of Treasury Stock Pursuant to the Provisions of Article 165, Paragraph 2 of the Companies Act)

During the period from December 1 to December 31, 2025, Daiichi Sankyo Company, Limited did not conduct any treasury stock acquisitions, with the number of shares acquired being 0 shares and the total acquisition cost being 0 yen.

Importance:
Page Updated: January 5, 2026
IR Disclosure Date: January 5, 2026

Key Figures

  • Type of Shares Targeted for Acquisition: Common shares of the company
  • Total Number of Shares Available for Acquisition: 80 million shares (upper limit)
  • Total Acquisition Cost of Shares: 200 billion yen (upper limit)

AI要約

Overview of Capital Policy

Daiichi Sankyo Company, Limited has resolved to acquire treasury stock based on the provisions of Article 165, Paragraph 2 of the Companies Act, with an upper limit of 80 million shares and a total acquisition cost ceiling of 200 billion yen, for the period from May 1, 2025, to March 24, 2026. However, during the period from December 1 to December 31, 2025, after comprehensively considering the market environment and stock price levels, no treasury stock acquisitions were conducted; the number of shares acquired was 0 shares and the total acquisition cost was 0 yen.

Future Outlook and Shareholder Returns

The company plans to continue making agile treasury stock acquisitions when deemed appropriate, taking into account the balance with growth investments such as research and development and considering market conditions and stock price levels. Furthermore, the company clarifies that the expected DOE of 8.5% or more for the fiscal year 2025 under the 5th Mid-term Management Plan (FY2021-FY2025) is expected to be achieved regardless of whether treasury stock acquisitions are carried out.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.